ArticleBrain, behavior, & immunity - health2021
GM1 ganglioside antibody and COVID-19 related Guillain Barre Syndrome - A case report, systemic review and implication for vaccine development.
Article in Brain, behavior, & immunity - health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Guillain Barre Syndrome as a Complication of COVID-19: A Systematic Review.The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques · 2022Pooled it
- Treatment Options for COVID-19-Related Guillain-Barré Syndrome: A Systematic Review of Literature.The neurologist · 2021Pooled it
- Post-COVID-19 Guillain-Barré Syndrome with GM1 and GD1b Antibodies: A Case Study and Literature Review.The American journal of case reports · 2025Review
- Guillain-barré syndrome (GBS) with antecedent chikungunya infection: a case report and literature review.Neurological research and practice · 2024Review
- Immunopathogenesis of viral infections in neurological autoimmune disease.BMC neurology · 2023Review
- A review of the potential neurological adverse events of COVID-19 vaccines.Acta neurologica Belgica · 2023Review
- Course and Treatment of a Rare Neurological Sequelae After COVID-19: Miller Fisher Syndrome.Cureus · 2022Article
- Bilateral facial palsy after COVID-19 vaccination.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Article
- Neurological sequela and disruption of neuron-glia homeostasis in SARS-CoV-2 infection.Neurobiology of disease · 2022Review
- Changes in ganglioside antibody positivity rates during the COVID-19 pandemic.Journal of neuroimmunology · 2022Article
- Atypical miller-fisher syndrome after COVID-19 and sleeve gastrectomy: Contribution of neurochemical markers to early diagnosis.Infectious medicine · 2022Article
- Guillain-Barré syndrome after mRNA-1273 (Moderna) COVID-19 vaccination: A case report.Clinical case reports · 2022Article
- COVID-19 and the peripheral nervous system. A 2-year review from the pandemic to the vaccine era.Journal of the peripheral nervous system : JPNS · 2022Review
- Article
- Article
- Elevation in sphingolipid upon SARS-CoV-2 infection: possible implications for COVID-19 pathology.Life science alliance · 2022Article
- Acute and chronic neurological disorders in COVID-19: potential mechanisms of disease.Brain : a journal of neurology · 2021Review
- Guillain-Barré Syndrome in the COVID-19 Pandemic.Neurology international · 2021Review
- Emerging Infection, Vaccination, and Guillain-Barré Syndrome: A Review.Neurology and therapy · 2021Review
- Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination.BMC neurology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGuillain Barre Syndrome (GBS) and Miller Fisher Syndrome (MFS) are emerging as known consequences of COVID-19 infection. However, there have been no reported cases with positive GM1 or GQ1b antibodies in the literature to date. Although clinically similar, the pathophysiology of COVID-19 related GBS and MFS may be significantly different from cases in the pre-pandemic era. CASE PRESENTATION: We present a patient with ascending areflexic weakness consistent with GBS with positive GM1 antibody. The patient had recovered from COVID-19 infection two weeks prior with mild viral illness and symptoms. Her weakness was isolated to the lower extremities and improved after intravenous immunoglobulin treatment. Patient recovered eventually.
conclusions- The general lack of reported ganglioside antibodies supports a novel target(s) for molecular mimicry as the underlying etiology, which raises the concern for possible vaccine induced complication. Whether the current GM1 positive case is a sequalae of COVID-19 or a mere coincidence is inconclusive. Further understanding of the disease mechanism of pandemic era GBS and MFS, including antigen target(s) of COVID-19, may be of utmost importance to the development of a safe COVID-19 vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.